James Gruber
Direttore Finanziario/CFO presso ETON PHARMACEUTICALS, INC.
Patrimonio netto: 44 741 $ in data 31/05/2024
Profilo
James R.
Gruber is currently the Chief Financial Officer, Secretary & Treasurer at Eton Pharmaceuticals, Inc. Prior to his current position, he worked as the Vice President & Controller at Horizon Therapeutics, Inc. Mr. Gruber completed his undergraduate degree at Indiana University and holds an MBA from Kellogg School of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 12/04/2024 | 12 603 ( 0.05% ) | 44 741 $ | 31/05/2024 |
Posizioni attive di James Gruber
| Società | Posizione | Inizio |
|---|---|---|
| ETON PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 11/04/2022 |
Precedenti posizioni note di James Gruber
| Società | Posizione | Fine |
|---|---|---|
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Comptroller/Controller/Auditor | - |
Formazione di James Gruber
| Kellogg School of Management | Masters Business Admin |
| Indiana University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ETON PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
- Borsa valori
- Insiders
- James Gruber
